MARKET

ONCO

ONCO

Onconetix
NASDAQ
1.610
-0.330
-17.01%
Opening 13:16 03/30 EDT
OPEN
1.470
PREV CLOSE
1.940
HIGH
1.750
LOW
1.180
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
74.29
52 WEEK LOW
1.180
MARKET CAP
1.12M
P/E (TTM)
-0.0194
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12h ago
Weekly Report: what happened at ONCO last week (0323-0327)?
Weekly Report · 13h ago
Onconetix files initial beneficial ownership statement; CEO David Allan White reports no securities beneficially owned
Reuters · 3d ago
Onconetix files Form 3 initial beneficial ownership statement; director Sammy Dorf reports no securities beneficially owned
Reuters · 3d ago
Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories
TipRanks · 3d ago
Onconetix Completes Reverse Stock Split to Maintain Listing
TipRanks · 3d ago
What's Going On With Onconetix Shares On Friday?
Benzinga · 3d ago
Market-Moving News for March 27th
Benzinga · 3d ago
More
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Webull offers Onconetix Inc stock information, including NASDAQ: ONCO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCO stock methods without spending real money on the virtual paper trading platform.